Heron Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Heron Therapeutics

08/11/2022 22:05

* Heron Therapeutics Inc  HRTX.OQ  reported a quarterly
adjusted
loss of 38 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 38 cents per share.
    * Revenue rose 14.3% to $26.56 million from a year ago;
analysts
expected $26.96 million. 
    * Heron Therapeutics Inc's reported EPS for the quarter was
a loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Heron Therapeutics Inc shares had fallen by 19.0% this
quarter and lost 62.5% so far this year.
    * The company reported a quarterly loss of $41.91 million.
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 10:05 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.38          -0.38          Met
 Jun. 30 2022      -0.50          -0.55          Missed
 Mar. 31 2022      -0.48          -0.63          Missed
 Dec. 31 2021      -0.58          -0.54          Beat